I just pulled up a bibliography on Hansjorg Wyss, and thought I'd post what Wikipedia said in the first two sentences.
"Hansjörg Wyss (pronounced HAHNZ-jorg VEES) (born 19 September 1935) is a Swiss entrepreneur and businessman. As of 2015, Wyss ranks #100 on the Forbes list of billionaires, with a net worth of approximately $11.4 billion, making him the second richest person in Switzerland behind Ernesto Bertarelli."
I followed your quoted search to come to the document dated January 1, 2014 but did not see an updated document. MAC is Medicare I presume, so your point is that Grafix Core and Prime are not covered in Medicare, therefore will have to be paid for by patient if these products are used? Were they covered in prior years, is this a continuation of non-coverage or something new. Please provide a link to the updated document so people can see what you saw. TIA.
True, either direction without considering catalysts, and fundamentals. With the apparent disconnect between our pps and the inherent value I am not giving equal consideration to a possible downside move coming out of this triangle. It would go against everything all of us know about SYN and therefore I heavily discount that possibility.
Great observation, this last week delivered a number of positives for the TA of our stock. I posted my observations in yesterday's post by Success_Now, should have posted it here. Depending on the news coming out of the JP Morgan conference, this time we could see a sustained rally with better likelihood of the gains holding. Despite news, we are way undervalued and should hold regardless. At some point, we'll go way higher. To trade or not to trade, that is the question.
Sentiment: Strong Buy
Here's the technical indicators that look compelling in chart:
1. Weekly shows 2 weeks of rising price per share, now over EMA = 9.
2. Two weeks now with higher low and higher highs.
3. Histogram behind MACD is going positive next week after 15 weeks under.
4. MACD is crossing up over signal line now, after 15 weeks of being below 0.
5. Slow Stochastic rising fast toward 50 line, definite bullish move,
6. KST is now making turn up, will cross over red signal line and head up next week.
Lastly, we have been in a long triangle consolidation pattern since May and are going to explode out of this triangle to upside before second week of February.
Serious replies only, TIA.
Mispriced also applies to NBS which I entered at 3.25, currently 3.67 having spiked to 4.10 on 12-30. My other pick OSIR was entered at $14.45 and is now over $3.00 higher, with a doubling in sight this year. Very confident in OSIR.
I have 75% of my shares at 3.49 but picked up another tranch at today's close 3.67. This stock is way undervalued and destined to get up toward the $10 handle with proper presentations of data and more trial advancements. I've learned to ignore the trolls. I have entered this stock into a yearly contest for best biotech perfomance in 2015, based on share price comparisons before Christmas. GLAL.
Great post, this year their story will get noticed, they already have demonstrated results, just need to get noticed and ASCO is the place to do it.
Waiting, glad this isn't my only stock, had a great day otherwise, and this too shall get exciting, next week is my guess.
Thanks mgm, another good read, looks like this one has outrun IDRA for the near term. Both had nice trading action today, now if SYN would get detached from its tether!
That YMB mini chart 'to the right' of our posting is awesomely powerful, and looking at the prior two swings up, we could hit our price target if the stock repeats its pattern in 2-3 months. Fundamentals look good, chart is consistent, we should be good to go. Looks like the board here isn't very active, so thanks for being here, and posting back.
Today we have a strong day, and our stock is now trading at 44.60. Aseipker was right, other than the flash down two days ago, right back up afterwards. I am reiterating my 65 target on the stock, by late March or April. Good luck all longs.
Sentiment: Strong Buy
It's been long anticipated, so much is riding on a good report to defeat the naysayers. I expect nothing less than great numbers pointing to the efficiency of this sales team, with their 'silver bullet' of PME. By end of January, we should have secured the $14 handle, built a new solid base camp here. GLAL.
And you sir are showing how little you know about conferences and what happens to stock prices othef company's who reveal important poster presentations on their drug candidates and the like. What a sloppy post posing as 'the truth'. Distortions, lies, and fear mongering is what you present.
You were just early, not wrong. In stocks you have to be right the idea AND the timing. If you get the timing wrong on the right idea, you wait it out or sell and quit whining. Which is it for you?
Confirmed, on my Schwab trading platform this came across the newswire at 5 PM. I saw doubters a couple days ago, here on YMB, it's a fact. Hopefully we will have some official announcements as to launch dates, and SNY's plans for an ad campaign, anticipated demand, etc.
Sentiment: Strong Buy
Our stock is anticipating it, I am looking forward to the catalyst of the conference and what comes of it, tired of seeing the early day gains give way. For those not having their position established yet, it is good, but I sense there is readiness among the others for this to ride the crest of the wave in biotech.